Results 211 to 220 of about 16,087 (221)

Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

Diabetes, Obesity and Metabolism, 2019
David Boulton, Hiddo Lambers Heerspink, Claire Dekkers   +2 more
exaly  

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT ‐2 study): 52‐week results from a randomized controlled trial

Diabetes, Obesity and Metabolism, 2020
Marcus Lind, Chantal Mathieu, Eiichi Araki   +2 more
exaly  

Efficacy and safety of dapagliflozin over 1 year as add‐on to insulin therapy in J apanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial

Diabetes, Obesity and Metabolism, 2017
Eiichi Araki, Yukiko Onishi
exaly  

Effects of Dapagliflozin on Cardiovascular Risk Factors

Postgraduate Medicine, 2013
Elise Hardy, Shamik Parikh, Eva Johnsson   +2 more
exaly  

The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels

Life Sciences, 2018
Won Sun Park, Won-Kyo Jung, Il-Whan Choi   +2 more
exaly  

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice

Diabetes, Obesity and Metabolism, 2014
exaly  

Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, 2016
Tarek Leil, Weifeng Tang
exaly  

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

Diabetes, Obesity and Metabolism, 2010
Marc Pfister
exaly  

Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes

Diabetes, Obesity and Metabolism, 2013
Dick De Zeeuw
exaly  

Dapagliflozin

2013
openaire   +1 more source